Selank

Overview

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Russia, built by appending a C-terminal Pro-Gly-Pro stabiliser to the immunoactive tuftsin fragment (Thr-Lys-Pro-Arg). The same Pro-Gly-Pro tail that gives Semax its extended half-life slows enzymatic degradation here too, turning a rapidly-cleaved tetrapeptide into a peptide with a usable in-vivo window. It is studied as a non-sedating anxiolytic and neuromodulator, with research lines spanning GABAergic and serotonergic signalling, BDNF expression, and enkephalin-degradation kinetics. For the offered or supplied lot, Vialdyne documents Selank acetate is released at ≥99.0% HPLC main-peak purity, with a batch COA bundling RP-HPLC peak integration, peptide-content assay, water (Karl Fischer), acetic-acid counter-ion, residual solvents, and endotoxin. LC-MS/MS sequence confirmation and the raw chromatogram are documented add-ons on the same lot for labs qualifying a new reference source.

Applications & buyer fit

Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

129954-34-3

Molecular Formula

C33H57N11O9

Molecular Weight

751.88 g/mol

Sequence

Thr-Lys-Pro-Arg-Pro-Gly-Pro

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 11 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2-3 minutes

MOQ

On request

Lead time

7–14 days

Storage

-20°C, protect from light

Certificate of Analysis

Representative COA previews for Selank; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Selank

VD260428-SK10174 · 99.37%

VerifiedRequest full COA →

Selank

VD260428-SK5173 · 99.05%

Regulatory note

Research-use-only reference material. Selank is registered as a medicine in the Russian Federation but is not approved by the FDA or EMA; not for human or veterinary use. Buyers are responsible for verifying regulatory status in the destination market.

Selected literature

1. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317.
3. Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23.
4. Ershov FI, Uchakin PN, Uchakina ON, Mezentseva MV, Alekseeva LA, Miasoedov NF. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24.
5. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31.
6. Kolik LG, Nadorova AV, Antipova TA, Kruglov SV, Kudrin VS, Durnev AD. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019;167(5):641-644.

Frequently asked questions